Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma

BACKGROUND AND PURPOSE: Glioblastoma multiforme (GBM) is the most aggressive subtype of malignant gliomas, with an average survival rate of 15 months after diagnosis. More than 90% of all GBMs have activating mutations in the MAPK/ERK pathway. Recently, we showed the allosteric MEK1/2 inhibitor bini...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Neurooncol
Main Authors: Bikhezar, Fatima, de Kruijff, Robin M., van der Meer, Astrid J. G. M., Torrelo Villa, Guzman, van der Pol, Susanne M. A., Becerril Aragon, Gabriel, Gasol Garcia, Ana, Narayan, Ravi S., de Vries, Helga E., Slotman, Ben J., Denkova, Antonia G., Sminia, Peter
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2019
Assuntos:
Laboratory Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6971148/
https://ncbi.nlm.nih.gov/pubmed/31875307
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-019-03365-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados